ILMN Stock to Gain From the Launch of Illumina Protein Prep Assay

Core Insights - Illumina, Inc. has launched Illumina Protein Prep, an assay aimed at enhancing next-generation sequencing (NGS)-based proteomics discovery, now available globally for researchers [1][2] - The launch follows Illumina's agreement to acquire SomaLogic, which strengthens its position in the proteomics market and supports its multiomics strategy [2][8] - Following the announcement, ILMN shares increased by 2.2%, indicating positive market reception and potential for continued upward momentum [3] Company Developments - Illumina Protein Prep utilizes SomaLogic's SOMAmer technology to measure 9,500 unique human protein targets, facilitating large-scale proteomics studies [5][8] - The company has processed approximately 30,000 samples with the Illumina Protein Prep 6K assay and over 6,000 samples with the 9.5K assay since early access began [6] - Illumina's market capitalization stands at $15.21 billion, with an earnings yield of 4.5%, significantly higher than the industry's -21.7% yield [4] Industry Context - The global proteomics market was valued at $27.8 billion in 2024 and is projected to grow at a CAGR of 12.9% by 2030, driven by the increasing prevalence of chronic diseases and demand for advanced diagnostics [10] - Researchers in the 100,000 Genomes Project have reported a 7.5% increase in diagnostic yield using Illumina Protein Prep, showcasing its effectiveness in improving diagnostic capabilities [9] Stock Performance - Over the past six months, ILMN shares have risen by 14.2%, contrasting with a 1.7% decline in the industry [12]